Jana McHugh, MB Bch BAO (Hons), MRCPI, FFR, Author at Grand Rounds in Urology

Jana McHugh, MB Bch BAO (Hons), MRCPI, FFR

The Institute of Cancer Research

London, England, UK

Dr. Jana McHugh is a Clinical Research Fellow in Oncogenetics at The Institute of Cancer Research and Honorary Senior Registrar in Clinical Oncology at the Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom. Dr Jana McHugh undertook her undergraduate medical training in the Royal College of Surgeons in Ireland (RCSI), and completed core medical training and higher specialist training in the Republic of Ireland in Radiation Oncology in 2020. Her current research with Professor Ros Eeles at The Institute of Cancer Research is in prostate cancer and the genetics associated with it. She works with the Oncogenetics team on the role of genetic variation in increased prostate cancer risk.

Talks by Jana McHugh, MB Bch BAO (Hons), MRCPI, FFR

Update on the PROFILE and IMPACT Studies

Posted by Jana McHugh, MB Bch BAO (Hons), MRCPI, FFR | Nov 2024

Jana McHugh, MB Bch BAO (Hons), MRCPI, FFR, discusses the IMPACT and PROFILE studies, which focus on prostate cancer risk and detection in genetically predisposed populations.

In this 11-minute presentation, McHugh shows that both studies emphasize early detection in genetically high-risk men, particularly BRCA mutation and Lynch syndrome carriers. Updated methodologies incorporate multi-ancestry PRS and expanded genetic sequencing to refine risk assessment and address disparities. These findings highlight the importance of precision screening in managing prostate cancer in diverse, high-risk populations.

PROFILE Study: Early Data on Targeted Screening for Prostate Cancer in Men of African and African Caribbean Ancestry

Posted by Jana McHugh, MB Bch BAO (Hons), MRCPI, FFR | Jan 2024

Jana McHugh, MB Bch BAO (Hons), MRCPI, FFR, presents the results from the ongoing PROFILE study, a multi-cohort study of targeted screening for groups of men at higher risk of developing prostate cancer. Specifically, Dr. McHugh presents the early results of PROFILE’s second cohort: Men of African and African Caribbean ancestry aged 40-69. Dr. McHugh begins by providing an overview of the design of the PROFILE study, explaining the criteria for inclusion in the study, the PSA-dependent and PSA-independent arms of the study, and treatment options for prostate cancer patients.

Dr. McHugh then turns to the role of polygenic risk scores in prostate cancer screening, focusing on genetic risk score and race. She notes that prostate cancer was detected in 39% of the PROFILE study’s second cohort thus far, and highlights the need for further exploration into the role of genetic risk score in prostate cancer screening.